GlassScriptPhysician profile
Kati L Langston
NPI 1285930750
$7,026.95
in general payments reported to CMS, 2019-2025
37 companies · $569 in 2025
The $569 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,783 · 2022: $1,681 · 2023: $1,733 · 2024: $1,261 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,507 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,507.43 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,317.79 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $903.15 | 2021-2024 | Cimzia |
| Janssen Biotech, INC. | $537.17 | 2021-2024 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $487.70 | 2021-2024 | |
| Abbvie INC. | $352.07 | 2021-2025 | |
| Lilly USA, LLC | $344.31 | 2021-2025 | Zepbound, Mounjaro, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.30 | 2021-2024 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $287.96 | 2021-2023 | Acthar |
| Pfizer INC. | $276.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $269.01 | 2021-2025 | Airsupra, Saphnelo, Farxiga |
| Novo Nordisk INC | $245.82 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $217.76 | 2021-2024 | Lupkynis |
| Organon LLC | $212.36 | 2021-2025 | Hadlima, Renflexis |
| Radius Health, INC. | $162.74 | 2021-2024 | Tymlos |
| Glaxosmithkline, LLC. | $140.04 | 2023-2024 | Benlysta |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $110.76 | 2022-2023 | Octagam Immune Globulin (Human) |
| Genentech USA, INC. | $95.28 | 2021-2023 | Actemra, Rituxan |
| Exact Sciences Corporation | $93.35 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $84.95 | 2025 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $61.48 | 2023-2024 | Orencia |
| Sobi, INC | $49.43 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $43.89 | 2024 | Purified Cortrophin Gel |
| Hikma Pharmaceuticals USA | $41.01 | 2021 | |
| Tersera Therapeutics LLC | $39.62 | 2022 | |
| Horizon Therapeutics Plc | $39.04 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $35.91 | 2021-2022 | |
| Sandoz INC. | $35.14 | 2023 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $32.80 | 2022-2024 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $28.16 | 2023-2024 | Quviviq |
| Mylan Institutional INC. | $25.88 | 2023 | |
| Bioventus LLC | $20.94 | 2023 | Supartz Fx Sodium Hyaluronate |
| Ibsa Pharma INC. | $20.52 | 2023 | Tirosint, Licart |
| Collegium Pharmaceutical, INC. | $18.95 | 2023 | Belbuca |
| Antares Pharma, INC. | $16.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.71 | 2024 | Trintellix |
| Depuy Synthes Sales INC. | $13.97 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.57 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kati Langston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.